Proteomic identification of carboxypeptidase E connects lipid-induced β-cell apoptosis and dysfunction in type 2 diabetes

Cell Cycle

Volumn 8, Issue 1, 2009, Pages 38-42

  Johnson, James D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cholesterol; ER stress; Palmitate; Pancreatic islets

Indexed keywords

CARBOXYPEPTIDASE H; PALMITIC ACID; LIPID; PALMITIC ACID DERIVATIVE;

APOPTOSIS; CELL FUNCTION; CELL SURVIVAL; CYTOTOXICITY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; GENETIC PREDISPOSITION; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEOMICS; SHORT SURVEY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; ARTICLE; BIOLOGICAL MODEL; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; APOPTOSIS; CARBOXYPEPTIDASE H; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN-SECRETING CELLS; LIPIDS; MODELS, BIOLOGICAL; PALMITATES; PROTEOMICS;

EID: 60749119458     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.1.7343     Document Type: Short Survey

References (102)

1. Zimmet P, Alberti KG and Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414:782-7.
2. Pick A, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998; 47:358-64.
3. Leonardi O, Mints G and Hussain MA. Beta-cell apoptosis in the pathogenesis of human type 2 diabetes mellitus. Eur J Endocrinol 2003; 149:99-102.
4. Butler AE, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102-10.
5. Marchetti P, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 2004; 89:5535-41.
6. Karasik A, et al. Genetically programmed selective islet beta-cell loss in diabetic subjects with Wolfram's syndrome. Diabetes Care 1989; 12:135-8.
7. Hofmann S, Philbrook C, Gerbitz KD and Bauer MF. Wolfram syndrome: structural and functional analyses of mutant and wild-type wolframin, the WFS1 gene product. Hum Mol Genet 2003; 12:2003-12.
8. Osman AA, et al. Wolframin expression induces novel ion channel activity in endoplasmic reticulum membranes and increases intracellular calcium. J Biol Chem 2003; 278:52755-62.
9. Ishihara H, et al. Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 2004; 13:1159-70.
10. Harding HP and Ron D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 2002; 51:455-61.
11. -/- mice reveals a role for translational control in secretory cell survival. Mol Cell 2001; 7:1153-63.
12. Stoy J, et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci USA 2007; 104:15040-4.
13. Takei D, et al. WFS1 protein modulates the free Ca(2+) concentration in the endoplasmic reticulum. FEBS Lett 2006; 580:5635-40.
14. Sandhu MS, et al. Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet 2007; 39:951-3.
15. Franks PW, et al. Replication of the association between variants in WFS1 and risk of type 2 diabetes in European populations. Diabetologia 2008; 51:458-63.
16. Scott LJ, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316:1341-5.
17. Saxena R, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316:1331-6.
18. Sladek R, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445:881-5.
19. Weedon MN, et al. Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. Am J Hum Genet 2003; 73:1208-12.
20. Horikawa Y, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000; 26:163-75.
21. Doria A, Patti ME and Kahn CR. The emerging genetic architecture of type 2 diabetes. Cell Metab 2008; 8:186-200.
22. Kopelman PG. Obesity as a medical problem. Nature 2000; 404:635-43.
23. Isomaa B. A major health hazard: the metabolic syndrome. Life Sci 2003; 73:2395-411.
24. Nadler ST and Attie AD. Please pass the chips: genomic insights into obesity and diabetes. J Nutr 2001; 131:2078-81.
25. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995; 44:863-70.
26. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46:3-10.
27. Boden G. Free fatty acids, insulin resistance and type 2 diabetes mellitus. Proc Assoc Am Physicians 1999; 111:241-8.
28. Boden G and Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32:14-23.
29. Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111:121-4.
30. Paolisso G, et al. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995; 38:1213-7.
31. Charles MA, et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 1997; 40:1101-6.
32. Brunham LR, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007; 13:340-7.
33. Vikman J, Jimenez-Feltstrom J, Nyman P, Thelin J and Eliasson L. Insulin secretion is highly sensitive to desorption of plasma membrane cholesterol. Faseb J 2008.
34. Xia F, et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology 2008; 149:5136-45.
35. Paolisso G, et al. Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 1995; 38:1295-9.
36. Biden TJ, Robinson D, Cordery D, Hughes WE and Busch AK. Chronic effects of fatty acids on pancreatic beta-cell function: new insights from functional genomics. Diabetes 2004; 53:159-65.
37. Maedler K, Oberholzer J, Bucher P, Spinas GA and Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 2003; 52:726-33.
38. Maedler K, et al. Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes 2001; 50:69-76.
39. Lupi R, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002; 51:1437-42.
40. Zhou YP and Grill V. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 1995; 80:1584-90.
41. Unger RH and Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 2001; 50:118-21.
42. Poitout V, et al. Regulation of the insulin gene by glucose and fatty acids. J Nutr 2006; 136:873-6.
43. Bollheimer LC, Skelly RH, Chester MW, McGarry JD and Rhodes CJ. Chronic exposure to free fatty acid reduces pancreatic beta cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin biosynthesis translation. J Clin Invest 1998; 101:1094-101.
44. Furukawa H, Carroll RJ, Swift HH and Steiner DF. Long-term elevation of free fatty acids leads to delayed processing of proinsulin and prohormone convertases 2 and 3 in the pancreatic beta-cell line MIN6. Diabetes 1999; 48:1395-401.
45. Prentki M and Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116:1802-12.
46. Jeffrey KD, et al. Carboxypeptidase E mediates palmitate-induced beta-cell ER stress and apoptosis. Proc Natl Acad Sci USA 2008; 105:8452-7.
47. Kharroubi I, et al. Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology 2004; 145:5087-96.
48. Eitel K, et al. Different role of saturated and unsaturated fatty acids in beta-cell apoptosis. Biochem Biophys Res Commun 2002; 299:853-6.
49. Shimabukuro M, Zhou YT, Levi M and Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998; 95:2498-502.
50. Cunha DA, et al. Initiation and execution of lipotoxic ER stress in pancreatic beta-cells. J Cell Sci 2008; 121:2308-18.
51. Karaskov E, et al. Chronic palmitate but not oleate exposure induces endoplasmic reticulum stress, which may contribute to INS-1 pancreatic beta-cell apoptosis. Endocrinology 2006; 147:3398-407.
52. El-Assaad W, et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 2003; 144:4154-63.
53. Choi SE, et al. Protective role of autophagy in palmitate-induced INS-1 beta cell death. Endocrinology 2008.
54. Johnson JD, et al. RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. J Biol Chem 2004; 279:24794-802.
55. Leung N, et al. Prolonged increase of plasma non-esterified fatty acids fully abolishes the stimulatory effect of 24 hours of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men. Diabetologia 2004; 47:204-13.
56. Listenberger LL, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA 2003; 100:3077-82.
57. Cnop M, Hannaert JC, Hoorens A, Eizirik DL and Pipeleers DG. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes 2001; 50:1771-7.
58. 2+-signaling in pancreatic beta-cells. Mol Cell Endocrinol 2003; 212:1-9.
59. Maestre I, et al. Mitochondrial dysfunction is involved in apoptosis induced by serum withdrawal and fatty acids in the beta-cell line INS-1. Endocrinology 2003; 144:335-45.
60. Lameloise N, Muzzin P, Prentki M and Assimacopoulos-Jeannet F. Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? Diabetes 2001; 50:803-9.
61. Carlsson C, Borg LA and Welsh N. Sodium palmitate induces partial mitochondrial uncoupling and reactive oxygen species in rat pancreatic islets in vitro. Endocrinology 1999; 140:3422-8.
62. Zhou YP and Grill VE. Palmitate-induced beta-cell insensitivity to glucose is coupled to decreased pyruvate dehydrogenase activity and enhanced kinase activity in rat pancreatic islets. Diabetes 1995; 44:394-9.
63. Zhou YP, Berggren PO and Grill V. A fatty acid-induced decrease in pyruvate dehydrogenase activity is an important determinant of beta-cell dysfunction in the obese diabetic db/db mouse. Diabetes 1996; 45:580-6.
64. Assimacopoulos-Jeannet F, et al. Fatty acids rapidly induce the carnitine palmitoyltransferase I gene in the pancreatic beta-cell line INS-1. J Biol Chem 1997; 272:1659-64.
65. Joseph JW, et al. Free fatty acid induced beta-cell defects are dependent on uncoupling protein 2 expression. J Biol Chem 2004.
66. Siman R, Flood DG, Thinakaran G and Neumar RW. Endoplasmic reticulum stress-induced cysteine protease activation in cortical neurons: effect of an Alzheimer's disease-linked presenilin-1 knock-in mutation. J Biol Chem 2001; 276:44736-43.
67. Kitao Y, et al. Expression of the endoplasmic reticulum molecular chaperone (ORP150) rescues hippocampal neurons from glutamate toxicity. J Clin Invest 2001; 108:1439-50.
68. Jayanthi S, Deng X, Noailles PA, Ladenheim B and Cadet JL. Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. Faseb J 2004; 18:238-51.
69. Bando Y, Katayama T, Aleshin AN, Manabe T and Tohyama M. GRP94 reduces cell death in SH-SY5Y cells perturbated calcium homeostasis. Apoptosis 2004; 9:501-8.
70. Hagman DK, Hays LB, Parazzoli SD and Poitout V. Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans. J Biol Chem 2005; 280:32413-8.
71. Yoshikawa H, et al. Effects of free fatty acids on beta-cell functions: a possible involvement of peroxisome proliferator-activated receptors alpha or pancreatic/duodenal homeobox. Metabolism 2001; 50:613-8.
72. Manco M, Calvani M and Mingrone G. Effects of dietary fatty acids on insulin sensitivity and secretion. Diabetes Obes Metab 2004; 6:402-13.
73. Johnson JD, et al. Increased islet apoptosis in Pdx1+/- mice. J Clin Invest 2003; 111:1147-60.
74. Johnson JD, et al. Insulin protects islets from apoptosis via Pdx1 and specific changes in the human islet proteome. Proc Natl Acad Sci USA 2006; 103:19575-80.
75. 2+ stores and arachidonic acid metabolism. J Clin Invest 1998; 101:1623-32.
76. Araki E, Oyadomari S and Mori M. Endoplasmic reticulum stress and diabetes mellitus. Intern Med 2003; 42:7-14.
77. Ozcan U, et al. Endoplasmic reticulum stress links obesity, insulin action and type 2 diabetes. Science 2004; 306:457-61.
78. Marchetti P, et al. The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 2007; 50:2486-94.
79. Naggert JK, et al. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat Genet 1995; 10:135-42.
80. Shen FS and Loh YP. Intracellular misrouting and abnormal secretion of adrenocorticotropin and growth hormone in cpefat mice associated with a carboxypeptidase E mutation. Proc Natl Acad Sci USA 1997; 94:5314-9.
81. Chen H, et al. Missense polymorphism in the human carboxypeptidase E gene alters enzymatic activity. Hum Mutat 2001; 18:120-31.
82. Gaulton KJ, et al. Comprehensive Association Study of Type 2 Diabetes and Related Quantitative Traits with 222 Candidate Genes. Diabetes 2008.
83. Zhou A, et al. Altered biosynthesis of neuropeptide processing enzyme carboxypeptidase E after brain ischemia: molecular mechanism and implication. J Cereb Blood Flow Metab 2004; 24:612-22.
84. Jin K, et al. Altered expression of the neuropeptide-processing enzyme carboxypeptidase E in the rat brain after global ischemia. J Cereb Blood Flow Metab 2001; 21:1422-9.
85. Lu H, Yang Y, Allister EM, Wijesekara N and Wheeler MB. The identification of potential factors associated with the development of type 2 diabetes: a quantitative proteomics approach. Mol Cell Proteomics 2008; 7:1434-51.
86. Asghar Z, et al. Insulin resistance causes increased beta-cell mass but defective glucosestimulated insulin secretion in a murine model of type 2 diabetes. Diabetologia 2006; 49:90-9.
87. Okada T, et al. Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. Proc Natl Acad Sci USA 2007; 104:8977-82.
88. Ueki K, et al. Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. Nat Genet 2006; 38:583-8.
89. Otani K, et al. Reduced beta-cell mass and altered glucose sensing impairs insulin secretory function in mice with pancreatic beta-cell knockout of the insulin receptor. Am J Physiol Endocrinol Metab 2003.
90. Aikin R, et al. Autocrine insulin action activates Akt and increases survival of isolated human islets. Diabetologia 2006; 49:2900-9.
91. Muller D, Jones PM and Persaud SJ. Autocrine anti-apoptotic and proliferative effects of insulin in pancreatic beta-cells. FEBS Lett 2006; 580:6977-80.
92. Beith JL, Alejandro EU and Johnson JD. Insulin Stimulates Primary beta-cell Proliferation via Raf-1 Kinase. Endocrinology 2008.
93. Johnson JD, et al. Suppressed insulin signaling and increased apoptosis in CD38-null islets. Diabetes 2006; 55:2737-46.
94. Johnson JD and Alejandro EU. Control of pancreatic beta-cell fate by insulin signaling: The sweet spot hypothesis. Cell Cycle 2008; 7.
95. Loh YP, Snell CR and Cool DR. Receptor-mediated targeting of hormones to secretory granules role of carboxypeptidase e. Trends Endocrinol Metab 1997; 8:130-7.
96. Goll DE, Thompson VF, Li H, Wei W and Cong J. The calpain system. Physiol Rev 2003; 83:731-801.
97. Chan SL and Mattson MP. Caspase and calpain substrates: roles in synaptic plasticity and cell death. J Neurosci Res 1999; 58:167-90.
98. Horikawa Y, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000; 26:163-75.
99. Setsuie R and Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int 2007; 51:105-11.
100. Bifsha P, et al. Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway. Cell Death Differ 2007; 14:511-23.
101. Wang YL, et al. Overexpression of ubiquitin carboxyl-terminal hydrolase L1 arrests spermatogenesis in transgenic mice. Mol Reprod Dev 2006; 73:40-9.
102. Kwon J, et al. Ubiquitin C-terminal hydrolase L-1 is essential for the early apoptotic wave of germinal cells and for sperm quality control during spermatogenesis. Biol Reprod 2005; 73:29-35.